2016
DOI: 10.1016/j.jval.2016.09.1104
|View full text |Cite
|
Sign up to set email alerts
|

Are treatment sequences, adverse events, long-term disease progression adequately considered in cost-effectiveness analyses of rheumatoid arthritis ?: A critical economic litterature review

Abstract: costs at one year from ID were € 5'480, 39% RA-related (€ 682 for drugs and 1'444 for hospitalisations), € 1'345 for ambulatory care, € 1'016 for other drugs and € 994 for other hospitalisations. ConClusions: Treatment patterns of RA patients in Italy are heterogeneous, with a variety of strategy options reported. More than half of healthcare costs in RA patients are not disease-related, suggesting that management of comorbidities is a cost-driver.

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles